B of A Securities Maintains Buy on Teva Pharmaceutical Indus, Raises Price Target to $42

B of A Securities analyst Jason Gerberry maintains Teva Pharmaceutical Indus (NYSE:TEVA) with a Buy and raises the price target from $38 to $42.